Differential Sensitivity of CD4+ and CD8+T Lymphocytes to the Killing Efficacy of Fas (Apo-1/CD95) Ligand+ Tumor Cells in B Chronic Lymphocytic Leukemia
B-chronic lymphocytic leukemia (B-CLL) is characterized by cellular and humoral immune defects resulting in increased rates of infection and disturbed immune surveillance against cancer cells as well as by the expansion of slowly proliferating tumor cells. We found increased Fas receptor (FasR) expr...
Saved in:
Published in | Blood Vol. 91; no. 11; pp. 4273 - 4281 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
01.06.1998
|
Online Access | Get full text |
Cover
Loading…
Abstract | B-chronic lymphocytic leukemia (B-CLL) is characterized by cellular and humoral immune defects resulting in increased rates of infection and disturbed immune surveillance against cancer cells as well as by the expansion of slowly proliferating tumor cells. We found increased Fas receptor (FasR) expression in peripheral blood CD4+and CD8+ cells of B-CLL patients compared with the equivalent cells of healthy donors. Although increased Fas receptor expression was significant in both T-lymphocytic subsets, only CD4+ cells from B-CLL patients underwent apoptosis after treatment with the agonistic Fas antibody CH11. In CD4+cells of B-CLL patients, the Fas-sensitivity also correlated with a CD4+/CD8+ ratio below the lower threshold of healthy individuals (<1.0). By contrast, FasR expression in the CD19+ fraction of B-CLL patients was downregulated compared with normal controls, and this was associated with an insensitivity to CH11-induced apoptosis. The B-CLL cell line EHEB as well as CD19+ cells from B-CLL patients constitutively expressed Fas ligand (FasL). The FasL was functionally active, as the B-CLL cell line as well as T-cell–depleted CD19+ B-CLL fractions were able to kill target T-acute lymphatic leukemia (T-ALL) cells in vitro. This effect was inhibited by the antagonistic FasR-antibody ZB4, the neutralizing anti-FasL monoclonal antibody (MoAb) NOK-2 or by transfection of the caspase inhibitor crmA. These data point to the fact that expression of FasL on CD19+B-CLL cells, together with enhanced susceptibility of CD4+ T cells toward FasL-bearing effector cells, are causally linked to the relative reduction of CD4+ cells occurring during B-CLL progression. These findings could explain the inversion of the ratio of CD4+/CD8+ cell numbers, which may be causally linked to the immune deficiency observed in these patients and to the expansion of the neoplastic clone in B-CLL. |
---|---|
AbstractList | B-chronic lymphocytic leukemia (B-CLL) is characterized by cellular and humoral immune defects resulting in increased rates of infection and disturbed immune surveillance against cancer cells as well as by the expansion of slowly proliferating tumor cells. We found increased Fas receptor (FasR) expression in peripheral blood CD4+and CD8+ cells of B-CLL patients compared with the equivalent cells of healthy donors. Although increased Fas receptor expression was significant in both T-lymphocytic subsets, only CD4+ cells from B-CLL patients underwent apoptosis after treatment with the agonistic Fas antibody CH11. In CD4+cells of B-CLL patients, the Fas-sensitivity also correlated with a CD4+/CD8+ ratio below the lower threshold of healthy individuals (<1.0). By contrast, FasR expression in the CD19+ fraction of B-CLL patients was downregulated compared with normal controls, and this was associated with an insensitivity to CH11-induced apoptosis. The B-CLL cell line EHEB as well as CD19+ cells from B-CLL patients constitutively expressed Fas ligand (FasL). The FasL was functionally active, as the B-CLL cell line as well as T-cell–depleted CD19+ B-CLL fractions were able to kill target T-acute lymphatic leukemia (T-ALL) cells in vitro. This effect was inhibited by the antagonistic FasR-antibody ZB4, the neutralizing anti-FasL monoclonal antibody (MoAb) NOK-2 or by transfection of the caspase inhibitor crmA. These data point to the fact that expression of FasL on CD19+B-CLL cells, together with enhanced susceptibility of CD4+ T cells toward FasL-bearing effector cells, are causally linked to the relative reduction of CD4+ cells occurring during B-CLL progression. These findings could explain the inversion of the ratio of CD4+/CD8+ cell numbers, which may be causally linked to the immune deficiency observed in these patients and to the expansion of the neoplastic clone in B-CLL. |
Author | Marschitz, Ingrid Villunger, Andreas Greil, Richard Henn, Traudl Egle, Alexander Tinhofer, Inge Kos, Marion |
Author_xml | – sequence: 1 givenname: Inge surname: Tinhofer fullname: Tinhofer, Inge organization: From the Laboratory of Molecular Cytology, Department of Internal Medicine, University of Innsbruck, Innsbruck, Austria – sequence: 2 givenname: Ingrid surname: Marschitz fullname: Marschitz, Ingrid organization: From the Laboratory of Molecular Cytology, Department of Internal Medicine, University of Innsbruck, Innsbruck, Austria – sequence: 3 givenname: Marion surname: Kos fullname: Kos, Marion organization: From the Laboratory of Molecular Cytology, Department of Internal Medicine, University of Innsbruck, Innsbruck, Austria – sequence: 4 givenname: Traudl surname: Henn fullname: Henn, Traudl organization: From the Laboratory of Molecular Cytology, Department of Internal Medicine, University of Innsbruck, Innsbruck, Austria – sequence: 5 givenname: Alexander surname: Egle fullname: Egle, Alexander organization: From the Laboratory of Molecular Cytology, Department of Internal Medicine, University of Innsbruck, Innsbruck, Austria – sequence: 6 givenname: Andreas surname: Villunger fullname: Villunger, Andreas organization: From the Laboratory of Molecular Cytology, Department of Internal Medicine, University of Innsbruck, Innsbruck, Austria – sequence: 7 givenname: Richard surname: Greil fullname: Greil, Richard organization: From the Laboratory of Molecular Cytology, Department of Internal Medicine, University of Innsbruck, Innsbruck, Austria |
BookMark | eNpdkNFOwjAUhhuDiYC-Qy9VstnTrdt6CQPUuMQL0dulbC1Utpasw2Rv4uM6kMTEm3P-_-J8yflGaGCskQjdA_EBEvqwrqwt_Q8OffVDGgd-CLCjLD_mfiRwgYbAaOIRQskADQkhkRfyGK7QyLlPQiAMKBui77lWSjbStFpU-E0ap1v9pdsOW4XTeTjBwpR9SCYrnHX1fmuLrpUOtxa3W4lfdFVps8ELpXQhitPVUjh8O91bDx7SOWd3ONObHjLBq0NtG5zKqnJYGzzD6baxRhd_4GOWh52stbhGl0pUTt6c9xi9Lxer9MnLXh-f02nmFTSOW68AFvGI04SxKKKMKlEWikXAaRmXPCCS9D-DVOGaiAiIAiLLkHECMRUCEh6M0eyXWzTWuUaqfN_oWjRdDiQ_us5PrvPedV_Pfv-5Dn4A1Fh16g |
CitedBy_id | crossref_primary_10_3389_fimmu_2021_738915 crossref_primary_10_1182_blood_V96_9_3168_h8003168_3168_3174 crossref_primary_10_4049_jimmunol_163_8_4115 |
Cites_doi | 10.1016/0022-1759(91)90325-A 10.1182/blood.V78.6.1569.1569 10.1016/0145-2126(90)90167-8 10.1182/blood.V84.8.2622.bloodjournal8482622 10.1002/eji.1830260332 10.1016/S0092-8674(00)81349-5 10.1007/BF00196352 10.1016/S0092-8674(00)81266-0 10.1126/science.7533326 10.1111/j.1365-2249.1995.tb05540.x 10.1182/blood.V84.1.220.bloodjournal841220 10.1038/373444a0 10.4049/jimmunol.149.11.3753 10.1016/0167-5699(95)80079-4 10.1038/373441a0 10.1182/blood.V74.2.786.786 10.1182/blood.V84.12.4249.bloodjournal84124249 10.4049/jimmunol.157.7.2749 10.1182/blood.V90.1.12 10.4049/jimmunol.158.10.4521 10.4049/jimmunol.129.5.2305 10.4049/jimmunol.159.3.1192 10.1038/nm1295-1279 10.1084/jem.182.5.1545 10.1016/0092-8674(91)90614-5 10.1126/science.275.5302.960 10.1182/blood.V57.3.418.418 10.1084/jem.178.6.2231 10.1038/374163a0 10.1111/j.1600-065X.1995.tb00684.x 10.1182/blood.V90.2.745 10.1002/ajh.2830290307 10.4049/jimmunol.158.10.4602 10.4049/jimmunol.122.3.1087 10.1182/blood.V89.4.1357 10.1016/0092-8674(93)90326-L 10.1084/jem.169.5.1747 10.1182/blood.V87.12.4959.bloodjournal87124959 10.1038/375078a0 |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.1182/blood.V91.11.4273.411k25_4273_4281 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Biology Anatomy & Physiology |
EISSN | 1528-0020 |
EndPage | 4281 |
ExternalDocumentID | 10_1182_blood_V91_11_4273_411k25_4273_4281 |
GroupedDBID | --- -~X .55 .GJ 0R~ 0SF 1CY 23N 2WC 4.4 53G 5GY 5RE 5VS 6J9 9M8 AAEDW AALRI AAQQT AAXUO AAYXX ABOCM ABVKL ACGFO ADBBV ADVLN AENEX AFFNX AFOSN AI. AITUG AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BTFSW C1A CITATION CS3 DIK DU5 E3Z EBS EJD EX3 F5P FDB FRP GS5 GX1 H13 IH2 J5H K-O KQ8 L7B LSO MJL N4W N9A OHT OK1 P2P R.V RHF RHI ROL SJN THE TR2 TWZ UCJ VH1 W2D W8F WH7 WOQ WOW X7M YHG YKV ZGI ZXP |
ID | FETCH-LOGICAL-c277t-c156969285566252fadcf56192d7d930e09711ef4b0a610f10ed4590172aa1893 |
ISSN | 0006-4971 |
IngestDate | Fri Aug 23 00:41:55 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c277t-c156969285566252fadcf56192d7d930e09711ef4b0a610f10ed4590172aa1893 |
PageCount | 9 |
ParticipantIDs | crossref_primary_10_1182_blood_V91_11_4273_411k25_4273_4281 |
PublicationCentury | 1900 |
PublicationDate | 1998-06-01 |
PublicationDateYYYYMMDD | 1998-06-01 |
PublicationDate_xml | – month: 06 year: 1998 text: 1998-06-01 day: 01 |
PublicationDecade | 1990 |
PublicationTitle | Blood |
PublicationYear | 1998 |
References | Latinis (2019112002552195800_B13) 1997; 158 Villunger (2019112002552195800_B28) 1997; 57 Walker (2019112002552195800_B18) 1997; 158 Estaquier (2019112002552195800_B9) 1996; 87 Aries (2019112002552195800_B10) 1995; 73 Nagata (2019112002552195800_B12) 1995; 267 Suda (2019112002552195800_B29) 1993; 75 Oyaizu (2019112002552195800_B31) 1994; 84 di Celle (2019112002552195800_B34) 1994; 84 Rothstein (2019112002552195800_B40) 1995; 374 Rathmell (2019112002552195800_B39) 1996; 87 Peller (2019112002552195800_B6) 1991; 78 Ju (2019112002552195800_B14) 1995; 373 Sloand (2019112002552195800_B8) 1997; 89 Matzinger (2019112002552195800_B24) 1991; 145 Brunner (2019112002552195800_B15) 1995; 373 Trentin (2019112002552195800_B35) 1994; 84 Miyawaki (2019112002552195800_B38) 1992; 149 Platsoucas (2019112002552195800_B3) 1982; 129 Cheson (2019112002552195800_B1) 1988; 29 Villunger (2019112002552195800_B20) 1997; 90 Amadori (2019112002552195800_B27) 1995; 1 Alderson (2019112002552195800_B37) 1993; 178 Martin (2019112002552195800_B25) 1995; 182 Muzio (2019112002552195800_B30) 1996; 85 Enari (2019112002552195800_B23) 1995; 375 Chiorazzi (2019112002552195800_B5) 1979; 122 Tötterman (2019112002552195800_B7) 1989; 74 Itoh (2019112002552195800_B11) 1991; 66 Yonehara (2019112002552195800_B26) 1989; 169 Sieg (2019112002552195800_B32) 1997; 159 Amasaki (2019112002552195800_B33) 1995; 99 Herrmann (2019112002552195800_B2) 1982; 49 Giordano (2019112002552195800_B36) 1997; 275 Kay (2019112002552195800_B4) 1981; 57 Hahn (2019112002552195800_B17) 1995; 146 Hashimoto (2019112002552195800_B42) 1997; 90 Strasser-Wozak (2019112002552195800_B22) 1995; 55 Hahne (2019112002552195800_B19) 1996; 26 Lynch (2019112002552195800_B16) 1995; 16 Saltman (2019112002552195800_B21) 1990; 14 Foote (2019112002552195800_B41) 1996; 157 |
References_xml | – volume: 145 start-page: 185 year: 1991 ident: 2019112002552195800_B24 article-title: The JAM test. A simple assay for DNA fragmentation and cell death. publication-title: J Immunol Methods doi: 10.1016/0022-1759(91)90325-A contributor: fullname: Matzinger – volume: 78 start-page: 1569 year: 1991 ident: 2019112002552195800_B6 article-title: Decreased CD45RA T-cells in B-cell chronic lymphatic leukemia patients: Correlation with disease stage. publication-title: Blood doi: 10.1182/blood.V78.6.1569.1569 contributor: fullname: Peller – volume: 14 start-page: 381 year: 1990 ident: 2019112002552195800_B21 article-title: Establishment of a karyotypically normal B-chronic lymphocytic leukemia cell line; evidence of leukemic origin by immunoglobulin gene rearrangement. publication-title: Leuk Res doi: 10.1016/0145-2126(90)90167-8 contributor: fullname: Saltman – volume: 84 start-page: 2622 year: 1994 ident: 2019112002552195800_B31 article-title: Cross-linking of CD4 molecules upregulates Fas antigen expression in lymphocytes by inducing interferon-γ and tumor necrosis factor-α secretion. publication-title: Blood doi: 10.1182/blood.V84.8.2622.bloodjournal8482622 contributor: fullname: Oyaizu – volume: 26 start-page: 721 year: 1996 ident: 2019112002552195800_B19 article-title: Activated B cells express functional Fas ligand. publication-title: Eur J Immunol doi: 10.1002/eji.1830260332 contributor: fullname: Hahne – volume: 87 start-page: 319 year: 1996 ident: 2019112002552195800_B39 article-title: Expansion or elimination of B cells in vivo: Dual roles for CD-40 and Fas ligands modulated by the B-cell antigen receptor. publication-title: Cell doi: 10.1016/S0092-8674(00)81349-5 contributor: fullname: Rathmell – volume: 73 start-page: 591 year: 1995 ident: 2019112002552195800_B10 article-title: Fas(CD95) expression on CD4+ T-cells from HIV-infected patients increases with disease progression. publication-title: J Mol Med doi: 10.1007/BF00196352 contributor: fullname: Aries – volume: 85 start-page: 817 year: 1996 ident: 2019112002552195800_B30 article-title: FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing complex. publication-title: Cell doi: 10.1016/S0092-8674(00)81266-0 contributor: fullname: Muzio – volume: 267 start-page: 1449 year: 1995 ident: 2019112002552195800_B12 article-title: The Fas death factor. publication-title: Science doi: 10.1126/science.7533326 contributor: fullname: Nagata – volume: 99 start-page: 245 year: 1995 ident: 2019112002552195800_B33 article-title: Up-regulated expression of Fas antigen (CD95) by peripheral naive and memory T-cell subsets in patients with systemic lupus erythematosus (SLE): A possible mechanism for lymphopenia. publication-title: Clin Exp Immunol doi: 10.1111/j.1365-2249.1995.tb05540.x contributor: fullname: Amasaki – volume: 84 start-page: 220 year: 1994 ident: 2019112002552195800_B34 article-title: Cytokine gene expression in B-cell chronic lymphocytic leukemia: Evidence of constitutive interleukin-8 (IL-8) mRNA expression and secretion of biologically active IL-8 protein. publication-title: Blood doi: 10.1182/blood.V84.1.220.bloodjournal841220 contributor: fullname: di Celle – volume: 373 start-page: 444 year: 1995 ident: 2019112002552195800_B14 article-title: Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. publication-title: Nature doi: 10.1038/373444a0 contributor: fullname: Ju – volume: 149 start-page: 3753 year: 1992 ident: 2019112002552195800_B38 article-title: Differential expression of apoptosis-related antigen on lymphocyte subpopulations in human peripheral blood. publication-title: J Immunol doi: 10.4049/jimmunol.149.11.3753 contributor: fullname: Miyawaki – volume: 16 start-page: 569 year: 1995 ident: 2019112002552195800_B16 article-title: Fas and FasL in the homeostatic regulation of immune responses. publication-title: Immunol Today doi: 10.1016/0167-5699(95)80079-4 contributor: fullname: Lynch – volume: 373 start-page: 441 year: 1995 ident: 2019112002552195800_B15 article-title: Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. publication-title: Nature doi: 10.1038/373441a0 contributor: fullname: Brunner – volume: 74 start-page: 786 year: 1989 ident: 2019112002552195800_B7 article-title: T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease. publication-title: Blood doi: 10.1182/blood.V74.2.786.786 contributor: fullname: Tötterman – volume: 84 start-page: 4249 year: 1994 ident: 2019112002552195800_B35 article-title: Expression and regulation of tumor necrosis factor, interleukin-2 and hematopoietic growth factor receptors in B-cell chronic lymphocytic leukemia. publication-title: Blood doi: 10.1182/blood.V84.12.4249.bloodjournal84124249 contributor: fullname: Trentin – volume: 157 start-page: 2749 year: 1996 ident: 2019112002552195800_B41 article-title: IL-4 induces Fas-resistance in B cells. publication-title: J Immunol doi: 10.4049/jimmunol.157.7.2749 contributor: fullname: Foote – volume: 90 start-page: 12 year: 1997 ident: 2019112002552195800_B20 article-title: Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: A potential mechanism of tumor-induced suppression of immune surveillance. publication-title: Blood doi: 10.1182/blood.V90.1.12 contributor: fullname: Villunger – volume: 57 start-page: 3331 year: 1997 ident: 2019112002552195800_B28 article-title: Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. publication-title: Cancer Res contributor: fullname: Villunger – volume: 49 start-page: 157 year: 1982 ident: 2019112002552195800_B2 article-title: Imbalance of T-cell subpopulations in patients with chronic leukemia of the B cell type. publication-title: Clin Exp Immunol contributor: fullname: Herrmann – volume: 158 start-page: 4521 year: 1997 ident: 2019112002552195800_B18 article-title: Role of Fas ligand (CD95L) in immune escape: The tumor cell strikes back. publication-title: J Immunol doi: 10.4049/jimmunol.158.10.4521 contributor: fullname: Walker – volume: 129 start-page: 2305 year: 1982 ident: 2019112002552195800_B3 article-title: Abnormal T-lymphocyte subpopulations in patients with B cell chronic lymphocytic leukemia: An analysis by monoclonal antibody. publication-title: J Immunol doi: 10.4049/jimmunol.129.5.2305 contributor: fullname: Platsoucas – volume: 159 start-page: 1192 year: 1997 ident: 2019112002552195800_B32 article-title: Viral regulation of CD95 expression and apoptosis in T-lymphocytes. publication-title: J Immunol doi: 10.4049/jimmunol.159.3.1192 contributor: fullname: Sieg – volume: 1 start-page: 1279 year: 1995 ident: 2019112002552195800_B27 article-title: Genetic control of the CD4/CD8 T-cell ratio in humans. publication-title: Nature Med doi: 10.1038/nm1295-1279 contributor: fullname: Amadori – volume: 182 start-page: 1545 year: 1995 ident: 2019112002552195800_B25 article-title: Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of Bcl-2 and Abl. publication-title: J Exp Med doi: 10.1084/jem.182.5.1545 contributor: fullname: Martin – volume: 66 start-page: 233 year: 1991 ident: 2019112002552195800_B11 article-title: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. publication-title: Cell doi: 10.1016/0092-8674(91)90614-5 contributor: fullname: Itoh – volume: 55 start-page: 348 year: 1995 ident: 2019112002552195800_B22 article-title: Splice site mutations in the glucocorticoid receptor gene causes resistance to GC-induced apoptosis in a human acute leukemia cell line. publication-title: Cancer Res contributor: fullname: Strasser-Wozak – volume: 275 start-page: 960 year: 1997 ident: 2019112002552195800_B36 article-title: Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. publication-title: Science doi: 10.1126/science.275.5302.960 contributor: fullname: Giordano – volume: 57 start-page: 418 year: 1981 ident: 2019112002552195800_B4 article-title: Abnormal T-cell subpopulation function in CLL: Excessive suppressor and deficient helper (T) activity with respect to B-cell proliferation. publication-title: Blood doi: 10.1182/blood.V57.3.418.418 contributor: fullname: Kay – volume: 178 start-page: 2231 year: 1993 ident: 2019112002552195800_B37 article-title: Fas transduced activation signals in normal human T-lymphocytes. publication-title: J Exp Med doi: 10.1084/jem.178.6.2231 contributor: fullname: Alderson – volume: 374 start-page: 163 year: 1995 ident: 2019112002552195800_B40 article-title: Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells. publication-title: Nature doi: 10.1038/374163a0 contributor: fullname: Rothstein – volume: 146 start-page: 57 year: 1995 ident: 2019112002552195800_B17 article-title: Mechanism and biological significance of CD4-mediated cytotoxicity. publication-title: Immunol Rev doi: 10.1111/j.1600-065X.1995.tb00684.x contributor: fullname: Hahn – volume: 90 start-page: 745 year: 1997 ident: 2019112002552195800_B42 article-title: Modulation of Bcl-2 protein by CD4 cross-linking: A possible mechanism for lymphocyte apoptosis in human immunodeficiency virus infection and for rescue of apoptosis by interleukin-2. publication-title: Blood doi: 10.1182/blood.V90.2.745 contributor: fullname: Hashimoto – volume: 29 start-page: 152 year: 1988 ident: 2019112002552195800_B1 article-title: Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored working group. publication-title: Am J Hematol doi: 10.1002/ajh.2830290307 contributor: fullname: Cheson – volume: 158 start-page: 4602 year: 1997 ident: 2019112002552195800_B13 article-title: Regulation of CD95 (Fas) ligand expression by TCR-mediated signaling events. publication-title: J Immunol doi: 10.4049/jimmunol.158.10.4602 contributor: fullname: Latinis – volume: 122 start-page: 1087 year: 1979 ident: 2019112002552195800_B5 article-title: T-cell helper defect in patients with chronic lymphocytic leukemia. publication-title: J Immunol doi: 10.4049/jimmunol.122.3.1087 contributor: fullname: Chiorazzi – volume: 89 start-page: 1357 year: 1997 ident: 2019112002552195800_B8 article-title: Role of Fas ligand and receptor in the mechanism of T-cell depletion in acquired immunodeficiency syndrome: Effect on CD4+ lymphocyte depletion and human immunodeficiency virus replication. publication-title: Blood doi: 10.1182/blood.V89.4.1357 contributor: fullname: Sloand – volume: 75 start-page: 1169 year: 1993 ident: 2019112002552195800_B29 article-title: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. publication-title: Cell doi: 10.1016/0092-8674(93)90326-L contributor: fullname: Suda – volume: 169 start-page: 1747 year: 1989 ident: 2019112002552195800_B26 article-title: A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. publication-title: J Exp Med doi: 10.1084/jem.169.5.1747 contributor: fullname: Yonehara – volume: 87 start-page: 4959 year: 1996 ident: 2019112002552195800_B9 article-title: Fas-mediated apoptosis of CD4+ and CD8+ T-cells from human immunodeficiency virus-infected persons: Differential in vitro preventive effect of cytokines and protease antagonists. publication-title: Blood doi: 10.1182/blood.V87.12.4959.bloodjournal87124959 contributor: fullname: Estaquier – volume: 375 start-page: 78 year: 1995 ident: 2019112002552195800_B23 article-title: Involvement of an ICE-like protease in Fas-mediated apoptosis. publication-title: Nature doi: 10.1038/375078a0 contributor: fullname: Enari |
SSID | ssj0014325 |
Score | 1.9501984 |
Snippet | B-chronic lymphocytic leukemia (B-CLL) is characterized by cellular and humoral immune defects resulting in increased rates of infection and disturbed immune... |
SourceID | crossref |
SourceType | Aggregation Database |
StartPage | 4273 |
Title | Differential Sensitivity of CD4+ and CD8+T Lymphocytes to the Killing Efficacy of Fas (Apo-1/CD95) Ligand+ Tumor Cells in B Chronic Lymphocytic Leukemia |
Volume | 91 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELfKEIMXBB0T3_IDICBKl7j5snjqx6ZCNyREh_ZWpbEzqrXJVNKH7i_hP-Tf4M52Wm-axICXyHVybtT79Xxn_3xHyCvRBoPnZYmb8TxzgyQQLhexdKNUxDxPBBMZBopHn6PBcfDpJDxpNH5ZrKVlNWllF9eeK_kXrUIf6BVPyf6FZteDQge0Qb9wBQ3D9UY67pvqJhUue39FKrqpBYEci37wmnXV3kCvn0Bz5ByuQHVltqp0Wgd0OYdTnZN7HzNJYOV3kDxI1Ups57x00cz1-jzEtYPD6akiQXad0XJeLpyenM0UmbbrmAy7my_Atlyeyfk0vbRrPDOl6TXxt_he5hoxH4tTi4O7-IGbGxfmxmK6FhlqTiA8YbEHBlK74DDrLsVss4qhj_XVbKu1ZY6w2p3uksYYY_Zsj3m2tea-jUrfsr0B00VRzDwOcZV__RyRYM5ZdS6g9Y370NFC0Vbg-2csHGN7XAtfTtB9ZeJc0xlVIJWwsRpzDGPCRzPOlTFvkdss5iGuEgy_bLa7gjbTpTbMj7BN3ps33fvze1oeleUajR6Q-yamoR0N0IekIYsm2ekUaVXOV_QNVSxjtX3TJHe6detur6412CTbR4bisUN-2qCmFqhpmVMAtUMBhdBInBG1AE2rkgKgqQE0rQGNUgBo-lbBeQ_B_I5qKDtUAZkqINNpQbvUAJlaQKY1kB-R44P9UW_gmvIhbsbiuHIzP4x4xFkSQsjCQpanIstDXDAQseBtT2L6NF_mwcRLIYjIfU-KAI9ixyxNffDjd8lWURbyMaE8SuJUijyIGOgqTXkIgYuYRBMhPFCS_4R8qFUwPtdZYsY3B8XT_5J-Ru5t_lDPyVa1WMoX4ChXk5cKZL8BnJmw6w |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Differential+Sensitivity+of+CD4%2B+and+CD8%2BT+Lymphocytes+to+the+Killing+Efficacy+of+Fas+%28Apo-1%2FCD95%29+Ligand%2B+Tumor+Cells+in+B+Chronic+Lymphocytic+Leukemia&rft.jtitle=Blood&rft.au=Tinhofer%2C+Inge&rft.au=Marschitz%2C+Ingrid&rft.au=Kos%2C+Marion&rft.au=Henn%2C+Traudl&rft.date=1998-06-01&rft.issn=0006-4971&rft.eissn=1528-0020&rft.volume=91&rft.issue=11&rft.spage=4273&rft.epage=4281&rft_id=info:doi/10.1182%2Fblood.V91.11.4273.411k25_4273_4281&rft.externalDBID=n%2Fa&rft.externalDocID=10_1182_blood_V91_11_4273_411k25_4273_4281 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-4971&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-4971&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-4971&client=summon |